Pacer Advisors Inc. Sells 30 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Pacer Advisors Inc. decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,782 shares of the medical research company’s stock after selling 30 shares during the quarter. Pacer Advisors Inc.’s holdings in Bio-Rad Laboratories were worth $914,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BIO. Blue Trust Inc. boosted its position in Bio-Rad Laboratories by 7.2% during the fourth quarter. Blue Trust Inc. now owns 1,132 shares of the medical research company’s stock worth $379,000 after purchasing an additional 76 shares during the period. SG Americas Securities LLC lifted its stake in shares of Bio-Rad Laboratories by 156.7% during the 4th quarter. SG Americas Securities LLC now owns 3,221 shares of the medical research company’s stock valued at $1,058,000 after buying an additional 1,966 shares in the last quarter. Ballentine Partners LLC boosted its holdings in Bio-Rad Laboratories by 5.2% in the 4th quarter. Ballentine Partners LLC now owns 714 shares of the medical research company’s stock worth $235,000 after buying an additional 35 shares during the period. UMB Bank n.a. grew its stake in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after buying an additional 32 shares in the last quarter. Finally, Polianta Ltd raised its holdings in Bio-Rad Laboratories by 21.2% during the 4th quarter. Polianta Ltd now owns 4,000 shares of the medical research company’s stock valued at $1,314,000 after acquiring an additional 700 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on BIO shares. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup raised their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average price target of $394.20.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $353.34 on Tuesday. The stock’s 50-day simple moving average is $340.61 and its two-hundred day simple moving average is $335.68. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The firm has a market capitalization of $9.89 billion, a P/E ratio of -12.93 and a beta of 0.90. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.